Nervagest Adverse Reactions

The pregabalin clinical programme involved over 12,000 patients who were exposed to pregabalin, of whom over 7,000 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 14% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
In Table 2, all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency very common (≥1/10); common (≥1/100 to ≤1/10); uncommon (≥1/1,000 to ≤1/100); rare (≤1/1,000); very rare (≤1/10,000); not known (cannot be estimated from the available data).
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products. (See Table 2.)

Click on icon to see table/diagram/image